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A conjugate of cancer-cell targeting cyclic disulphide nona-
peptide c(CRWYDENAC) consisting of nine L-amino acids with
the photoactive succinate platinum(IV) complex trans,trans-
[Pt(N3)2(py)2(OH)(succinate)] (Pt-cP) has been synthesised and
characterised. The conjugate was stable in dark, but released suc-
cinate–peptide and Pt(II) species upon irradiation with visible light,
and formed photoproducts with guanine. Conjugate Pt-cP exhibi-
ted higher photocytotoxicity than parent complex trans,trans,
trans-[Pt(N3)2(OH)2(py)2] (FM-190) towards cancer cells, including
ovarian A2780, lung A549 and prostate PC3 human cancer cells
upon irradiation with blue light (465 nm, 17.28 J cm−2) with IC50
values of 2.8–22.4 μM and the highest potency for A549 cells.
Even though the dark cellular accumulation of Pt-cP in A2780 cells
was lower than that of parent FM-190, Pt from Pt-cP accumulated
in cancer cells upon irradiation to a level >3× higher than that from
FM-190. In addition, the cellular accumulation of Pt from Pt-cP
was enhanced ca. 47× after irradiation.
Photoactive diazido platinum(IV) prodrugs oﬀer potential for
improved treatment of cancer due to their high stability and
low toxicity in the dark, potent photocytotoxicity, and novel
mechanism of action which has the possibility to overcome
cisplatin resistance in cancer cells.1–6 Among them, trans,trans,
trans-[Pt(N3)2(OH)2(py)2] (FM-190) is a promising prodrug can-
didate,7 which can be activated by visible light with a high
photocytotoxicity index. Derivatisation of the detachable axial
ligands in platinum(IV) prodrugs is now a common strategy to
enhance their pharmacological properties.8–12 For example,
conjugation of FM-190 to αvβ3 and αvβ5 integrin-selective RGD-
containing peptides introduces a preference towards
SK-MEL-28 melanoma cancer cells that overexpress the αvβ3
integrin,13 and incorporation of a TEMPO radical can enhance
the photocytotoxicity.14 FM-190 has also been conjugated to
drug delivery upconversion-luminescent nanoparticles,15
hydrogels,16 and block copolymer micelles17 for activation
with longer wavelength and improved selectivity.
Integrins are not only transmembrane receptors that facilitate
cell–cell and cell–matrix adhesion,18–20 but also regulators of
cancer progression signalling pathways.21 Thus, integrins play an
important role in cancer progression and metastasis. The over-
expression of integrins on cancer cells provides a useful diagnos-
tic and therapeutic avenue to cancer therapy.22–25 The integrin α6
receptor is reported to be overexpressed in various cancer cell
lines,26–28 including ovarian, lung, prostate and other cancers,
and promotes the migration, invasion and survival of cancer cells.
The tumour-specific homing cyclic peptide c(CRWYDENAC)
targets the integrin α6 receptor, using the sequence RWY (Arg–
Trp–Tyr) as binding site.29 RWY-grafted polymeric nano-
particles encapsulating a cisplatin prodrug display a 100-fold
increase in cytotoxicity towards integrin α6-overexpressing
nasopharyngeal carcinoma compared to free cisplatin.29
Here we have synthesised and characterised Pt-cP, a conju-
gate of a photoactive trans-diazido platinum(IV) complex with
the cyclic peptide c(CRWYDENAC), via amide bond formation
between the free carboxyl group of the Pt-bound axial succi-
nate and the N-terminal amino group of the peptide. All of
amino acids in the peptide have the L-configuration.
Photodecomposition and photoreactions with the nucleotide
guanosine 5′-monophosphate (5′-GMP) were investigated,
since guanine bases are potential DNA targets for Pt(II) photo-
products. The photocytotoxicity and cellular accumulation in
integrin α6-overexpressing cancer cell lines were studied in
comparison with the parent complex FM-190. We show that
the incorporation of the cyclic peptide as an axial ligand
enhanced the photocytotoxicity and cancer cellular accumu-
lation of this photoactive diazido platinum(IV) prodrug.
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The synthetic route for photoactive platinum(IV) complex Pt-
cP is summarised in Scheme 1. FM-NHS was prepared accord-
ing to a procedure similar to that reported previously.15 The
N-hydroxysuccinimide (NHS) active ester of trans,trans,trans-
[Pt(N3)2(py)2(OH)(succinate)] with one axial carboxyl group was
prepared by reaction with EDC, NHS and DMAP to generate
FM-NHS and purified by column chromatography on silica gel.
The coupling was carried out by stirring freshly prepared
FM-NHS with cyclic peptide c(CRWYDENAC) in DMF with
DIPEA under nitrogen for 36 h. The resulting yellow solid pos-
sessed good HPLC purity (94%, Fig. S1, ESI†), and was charac-
terised by ESI-HRMS, 1H NMR and UV-vis spectroscopy. The
ions [M + 2H]2+ (855.7493) and [M + H]+ (1710.4919) were
detected by HR-MS (Fig. 1a and Fig. S2, ESI†). The m/z values
and the isotopic mass distribution pattern of Pt are in good
agreement with the calculated spectra. A full assignment of
the 1H NMR peaks for the cyclic peptide peptide in DMSO-d6
was not attempted, but the doublet at 8.81 ppm ( J = 5.4 Hz)
and the triplets at 8.25 ppm ( J = 7.6 Hz) and 7.81 ppm ( J =
6.6 Hz) can be assigned to the α, γ and β protons, respectively,
of the pyridine ligands (Fig. S3, ESI†). The singlet at 10.7 ppm
is ascribed to the NH of the Trp indole ring and the NH amide
proton signals appear between 6.5 and 9.0 ppm. In addition,
in a mixture of 80% DMSO-d6 and 20% D2O (v/v), aromatic
protons assigned to pyridine, and Trp and Tyr amino acid resi-
dues confirm the conjugation of the Pt(IV) fragment to the
cyclic peptide (Fig. S4, ESI†). The absorption band at 290 nm
(30 435 M−1 cm−1) for Pt-cP in phenol red-free RPMI-1640 cell
culture medium with 5% DMSO (v/v) present to aid solubility,
is mainly assignable to a LMCT (N3 → Pt
IV) transition (Fig. 1b).
The cyclic peptide displayed an absorption band at 278 nm
due to Trp and Tyr side chains, and also contributed to the
absorption band for Pt-cP at 290 nm.
The dark stability and photodecomposition of Pt-cP in
phenol red-free RPMI-1640 were monitored by UV-vis spec-
troscopy. The absorption spectra of Pt-cP exhibited little
change in the dark over 2 h, indicating its dark stability
(Fig. 2a). However, a gradual decrease in intensity of absorp-
tion at 290 nm was observed upon irradiation with blue light
(420 nm), which suggested the photo-reduction of Pt(IV) to
Pt(II) and release of azide ligands (Fig. 2b).
The photoproducts from reactions of Pt-cP and 5′-GMP
(guanosine 5′-monophosphate) were investigated by LC-MS
(Fig. S5 and Table S1, ESI†). An aqueous solution of Pt-cP
(30 μM) and 2 mol equiv. of 5′-GMP was irradiated with
blue light (420 nm) for 1 h at 298 K. Then the products were
analysed by reverse-phase LC-MS. Upon 1 h irradiation, the
peak assigned as Pt-cP (retention time = 12.7 min) disappeared
and the intact succinate–c(CRWYDENAC) moiety (m/z =
1257.28) was released (Fig. S5†). The Pt-GMP adducts
Scheme 1 The synthetic route for photoactive conjugate Pt-cP. (1)
Succinic anhydride, DMF, 348 K, overnight; (2) EDC, NHS, DMAP, DMF,
N2, 298 K, overnight; (3) c(CRWYDENAC), DIPEA, DMF, N2, 298 K, 36 h.
Fig. 1 (a) Observed and calculated HR-ESI mass spectra for the molecular ion [M + 2H]2+ of Pt-cP; (b) UV-vis spectra of the conjugate Pt-cP (red)
and the free cyclic peptide (black) in phenol red-free RPMI-1640 cell culture medium at 298 K.
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{PtII(N3)(py)2(GMP)}
+ (758.22) and {PtII(OC(O)H)(py)2(GMP)}
+
(762.16) were detected (GMP in MS formula is considered
neutral unless otherwise stated, and the formic acid arises
from the mobile phase). No apparent diﬀerences between the
Pt-GMP adducts formed by the photoreaction between Pt-cP
and 5′-GMP compared with similar reactions of the parent
complex FM-190 were observed, which suggested that conju-
gation of cyclic peptide in an axial position did not aﬀect the
photochemical reactions of the platinum(IV) centre and
binding to the DNA/RNA base guanine after irradiation.7
Conjugate Pt-cP exhibited promising dark stability and
photocytotoxicity towards several human cancer cell lines,
including A2780 ovarian, A549 lung and PC3 prostate human
cancer cell lines. The dose-dependent inhibition of cell viabi-
lity determined by the sulforhodamine B (SRB) colorimetric
assay for conjugate Pt-cP in comparison with the parent
complex FM-190 both in the dark and after irradiation, is sum-
marised in Table 1. Both complexes were relatively non-toxic
towards all cancer cell lines in the dark with IC50 values
>100 μM. However, the cytotoxicity of both complexes was sig-
nificantly enhanced after 1 h irradiation with blue light
(465 nm, 17.28 J cm−2). Importantly, the photocytotoxicity of
conjugate Pt-cP (IC50 = 6.6 μM for A2780, 2.8 μM for A549, and
22.4 μM for PC3) was greater than that of the parent complex
FM-190 (IC50 = 7.1 μM for A2780, 51.9 μM for A549, and
55.6 μM for PC3) with photocytotoxicity indices (PI) of >15.2,
35.7 and 4.5 towards A2780 ovarian, A549 lung and PC3 pros-
tate cancer cells, respectively. These results indicate that the
conjugation with the cyclic peptide c(CRWYDENAC) enhances
the photocytotoxicity of this platinum(IV) prodrug without
reducing its dark stability. Notably, under the conditions used
(short treatment times), the clinical drug cisplatin was inactive
(Table 1). Low dark cytotoxicity (IC50 > 100 μM) of Pt-cP in
healthy MRC5 lung cells was observed, which might allow
selectivity towards cancer cells to be achieved by spatially-
directed irradiation (Table 1).
Cellular accumulation of metallodrugs often plays an
important role in their antiproliferative potency. Pt accumu-
lation by A2780 ovarian and A549 lung cancer cells in the dark
was investigated when they were exposed to photoactive plati-
num(IV) complexes at the same Pt concentration (10 μM) for
Fig. 2 (a) Dark stability over 2 h and (b) photodecomposition with blue light (420 nm, over 1 h) of conjugate Pt-cP in phenol red-free RPMI-1640
determined by UV-vis spectroscopy; (c) time dependence of the absorbance at 290 nm.
Table 1 IC50 values and photocytotoxicity indices (PI) for conjugate Pt-
cP and the parent complex FM-190 obtained after 1 h incubation, 1 h
irradiation (465 nm) and 24 h recovery. CDDP (cisplatin) was used as a
reference
Cell line
IC50
a (μM)
Pt-cP FM-190 CDDP
A2780 Dark >100 >100b >100b
Irrad. 6.6 ± 0.2 7.1 ± 0.4b >100b
PI >15.2 >14.1 —
A549 Dark >100 >100 >100
Irrad. 2.8 ± 0.2 51.9 ± 2.5 >100
PI >35.7 >1.9 —
PC3 Dark >100 >100 >100
Irrad. 22.4 ± 2.2 55.6 ± 0.9 >100
PI >4.5 >1.8 —
MRC5 Dark >100 >100b >100b
aData are from three independent experiments. bData are adapted
from ref. 14 and 30.
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1 h (Table 2). The cellular accumulation of Pt from conjugate
Pt-cP (2.5 ng per 106 cells) in A549 cells was 2.5× higher than
that from the parent complex, which is consistent with the
high photocytotoxicity of the conjugate in A549 cells. In con-
trast, a very low Pt accumulation was detected in A2780 cells
after treatment with Pt-cP (0.17 ng per 106 cells). For compari-
son, parent complex FM-190 exhibited similar accumulation in
both cell lines, which indicates the selectivity of the conjugate.
However, similar photocytotoxicity was observed for Pt-cP and
FM-190 in A2780 cells.
To investigate the eﬀect of light exposure on accumulation,
duplicate plates of A2780 ovarian cancer cells were exposed to
conjugate Pt-cP for 1 h in the dark at the IC50 concentration
(6.6 µM). Then some plates were irradiated with blue light
(465 nm) for 1 h, while other plates treated with the same drug
were left in the dark for comparison (Table 3). It is notable
that the cellular accumulation of Pt was ca. 47× enhanced after
irradiation (9.4 ng Pt per 106 cells after irradiation, 0.2 ng Pt
per 106 cells in the dark), probably because the Pt(II) photo-
products are more reactive towards intracellular biomolecules
than the Pt(IV) prodrug and were less readily eﬄuxed from the
cells.31 In addition, the cellular accumulation of parent
complex FM-190 (as Pt) in the absence of light (0.9 ng Pt per
106 cells) was ca. 3× higher than in the presence of light (2.7
ng Pt per 106 cells), on treatment of cells at IC50 concentration
(7.1 µM). Platinum accumulation of the conjugate was lower
than that of the parent complex before irradiation. However,
the amount of Pt from conjugate Pt-cP accumulated in A2780
cells is >3× higher than that from parent complex FM-190
(Table 3) after irradiation. This increased accumulation
resulted in the similar photocytotoxicity of conjugate Pt-cP
with FM-190, and suggested that the cyclic peptide might
deliver Pt to diﬀerent parts of the cell compared to FM-190
alone, as anticipated.
In summary, we have prepared and characterised a photo-
active conjugate between a trans-diazido platinum(IV) prodrug
and a receptor-targeting cyclic RWY (Arg–Trp–Tyr) nona-
peptide Pt-cP. The conjugate exhibited high dark stability, but
was potently photocytotoxic towards several human cancer cell
lines with IC50 values of 2.8–22.4 µM. The highest photocyto-
toxicity and accumulation of the conjugate was observed for
A549 cells. Light irradiation promoted the cellular accumu-
lation of Pt from Pt-cP significantly (ca. 3× that of parent
prodrug FM-190). This work suggests that cancer cell-targeting
cyclic peptides can improve the photo-cytotoxicity and photo-
accumulation of photoactive platinum(IV) complexes, and their
photo-selectivity towards cancer cells.
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